EmVenio Insights
Explore our resources, including blogs, whitepapers, press, videos, and more.
">EmVenio Research Partners with ClearDATA to Secure Clinical Trials in the Heart of Underserved Communities
EmVenio doubles minority participation in clinical trials with geographic and cultural accessibility solution protected by the ClearDATA Managed Health Cloud AUSTIN, Texas, March 30, 2023 (GLOBE NEWSWIRE) — ClearDATA®, the first and most comprehensive provider of healthcare-specific managed cloud, compliance and…
">EmVenio featured in CenterWatch
EmVenio president Thad Wolfram spoke to CenterWatch about our innovative approach to expand access and diversity in clinical trials through our fleet of mobile community research sites. Thad discussed how EmVenio was formed and its mission behind the work we…
">EmVenio Research prioritizes improving access to clinical research in Orlando with opening of community research site
DURHAM, N.C., March 6, 2023 /PRNewswire/ — EmVenio Research activated a mobile community research site in Orlando, Florida, as part of a concerted effort to maximize diversity, equity and inclusion in research studies and deliver clinical trial access to diverse and underserved communities. EmVenio will…
">Activated Sites
EmVenio Research is committed to helping you achieve your DEI objectives and meet enrollment goals. With our 10 active Community Research Sites located in geographies providing access to underserved and difficult to reach populations, we enable you to enroll the…
">SCOPE Summit 2023
The SCOPE 2023 Summit was a major success, with attendees from all over the world gathering to learn more about the latest developments in the clinical trial industry. The event was full of memorable moments, from keynotes, workshops, and demos…
">EmVenio Research prioritizes improving access to clinical research with the opening of the Claremont Community Research Site
DURHAM, N.C., Feb. 21, 2023 /PRNewswire/ — EmVenio Research activated a mobile community research site in Claremont, California, as part of a concerted effort to maximize diversity, equity and inclusion in research studies and deliver clinical trial access to diverse and underserved communities. EmVenio will…
">EmVenio prioritizes inclusion in clinical research with new patient-centric model
DURHAM, N.C., Feb. 16, 2023 – In an effort to maximize diversity, equity and inclusion in clinical research, EmVenio Research activated 10 community research sites among diverse populations across the United States. This concerted effort marks the value EmVenio’s services…
">GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial
Mobile Community Clinical Research Facility to be Deployed in California Atlanta, GA, February 15, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, and EmVenio Research, a patient-focused decentralized trial…
">Putting Patients First: The Benefits of Decentralized Clinical Trials
Clinical trials are essential for the discovery of new treatments and support the development of new life-saving drugs and medical devices that can benefit millions worldwide. But one of the greatest challenges in clinical research is the lack of representation.
">Never Let A Good Crisis Go To Waste
That quote has often been attributed to Sir Winston Churchill as he and other world leaders worked to help gather interest and generate momentum to form the United Nations after WWII. The goal of these leaders was to learn from the…
">Ripple Enterprise to be an integral part of EmVenio Research’s Decentralized Clinical Trial (DCT) Platform
Agreement signed for Ripple Enterprise patient engagement software to be deployed by EmVenio Research, making decentralized trials rapid and scalable. ANN ARBOR, MI, AND DURHAM, NC, USA, September 15, 2022 /EINPresswire.com/ — Ripple Science, a digital clinical trial software company,…